SCHEMBL15079557

SCHEMBL15079557

CCOC(=O)C1(N(C)C(=O)OCc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
OPRM1 P35372 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRD1 P41143 3/20 0.42
OPRK1 P41145 3/20 0.42
SLC22A1 O15245 2/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
KCNH2 Q12809 1/20 0.42
RORC P51449 2/20 0.42
SIGMAR1 Q99720 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
DDB1 Q16531 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1189285 0.88 ABCB1 (0.45) ALDH1A1OPRM1OPRD1OPRK1RORC
SCHEMBL2906426 0.86 ABCB1 (0.44) ALDH1A1OPRM1OPRD1OPRK1RORC
SCHEMBL20582129 0.86 ALDH1A1 (0.49) ALDH1A1LMNAL3MBTL1MEN1KMT2A
SCHEMBL2906427 0.85 ABCB1 (0.44) ALDH1A1OPRM1OPRD1OPRK1RORC
SCHEMBL15114465 0.85 ALDH1A1 (0.45) ALDH1A1L3MBTL1MAPTHPGDDDB1
SCHEMBL15114480 0.82 ALDH1A1 (0.51) ALDH1A1OPRM1MAPTHPGDDDB1
SCHEMBL15114479 0.82 L3MBTL1 (0.43) ALDH1A1L3MBTL1SMN1; SMN2MAPTHPGD
SCHEMBL3991791 0.81 ALDH1A1 (0.46) ALDH1A1L3MBTL1KMT2ARORCSIGMAR1
SCHEMBL19031238 0.81 ALDH1A1 (0.46) ALDH1A1L3MBTL1KMT2ARORCSIGMAR1
SCHEMBL2906265 0.80 ABCB1 (0.40) ALDH1A1OPRM1OPRD1OPRK1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763998-B1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2016-04-27 EP disclosed
US-9216997-B2 Tri-heterocyclic derivatives, preparation process and uses thereof SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2015-12-22 US disclosed
US-9216997-B2 Tri-heterocyclic derivatives, preparation process and uses thereof SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2015-12-22 US disclosed
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2014-11-06 US disclosed
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2014-11-06 US disclosed
WO-2013091502-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF MAP3K15, MAP3K1, MAP3K5 ALDH1A1 2288/4885LMNA 2436/4885POLB 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.